


# **NAFLDsym 2A**

**NAFLDsym® is Quantitative Systems Pharmacology (QSP) Software Capable of Exploring and Predicting Efficacy for Novel NASH Treatments**




## Sound Science

- NAFLDsym v2A available, including steatosis, lipotoxicity, inflammation, and fibrosis
- NAFLDsym is used to evaluate the efficacy potential of new drug candidates to treat non-alcoholic fatty liver disease (NAFLD) and non alcoholic steatohepatitis (NASH)
- NAFLDsym can be used to better understand NAFLD/NASH pathophysiology, progression, and treatment mechanisms
- DILIsym Services, Inc. has leveraged its long standing expertise in liver physiology and metabolic diseases to develop NAFLDsym
- Successful collaborations with 4 large pharmaceutical companies to date

## Capable - Key Mechanisms Included in NAFLDsym v2A:

- Fibrosis
- Steatosis
- Lipotoxicity
- Inflammation
- >1000 simulated patients with pathophysiologic variability, representing fibrosis stages F0-F4
- Biomarkers (e.g., MRE, MRI, ALT, NAS, Pro-C3)
- Weight loss/gain and its effect on regression progression
- Parallel prediction of compound hepatotoxicity risk is possible with coordinated use of DILIsym®



## Application Driven

- Optimize clinical trial protocols by determining favorable dosing paradigms and outcome measurement frequency
- Evaluate targets and/or specific compounds utilizing key laboratory and/or clinical data describing DMPK and pharmacodynamic characteristics
- Evaluate combination therapy approaches
- Compare efficacy in different patient groups (i.e., stratification by NAS, by fibrosis score)
- Prioritize compounds and targets

NAFLDsym Predicts Efficacy via the Intersection Between Exposure, PD, and Inter-Patient Pathophysiologic Variability